Skip to content
Screener

AnaptysBio, Inc. ANAB License — Revenue

Similar metrics at other companies

Under Armour logo
UAALicense revenues — Revenue
$24.81M+1.8%
CWA
CWANLicense — Revenue
$2.4M+153%
Dianthus Therapeutics logo
DNTHLicense — Revenue
$463K-60.2%
NetSol Technologies logo
NTWKLicense — Revenue
$4.73M+394,592%
eGain logo
EGANLicense — Revenue
$20.92M+6.9%
TG Therapeutics logo
TGTXLicense — Revenue
$4.54M+97.0%

Other financials

Income statement

See full
Revenue$25.6M-8.0%
Operating income-$34.6M-25.8%
Net income-$52.9M-34.5%
EPS (diluted)-$1.84-43.8%

Balance sheet

See full
Cash & equivalents$248.5M+152%
Total debt$13.6K-99.9%
Total equity$12.7M-62.5%
Total assets$329.7M-21.9%

Cash flow

See full
Operating cash flow-$25.9M-142%
CapEx$17.0K-51.4%
Free cash flow-$25.9M-142%

Valuation

See full
Market cap$1.62B+145%
Enterprise value$1.37B+117%
P/S+1.6×

Profitability

See full
Operating margin17.6%+9.6pp
Net margin-49.9%-22.6pp
FCF margin1.9%+1.0pp

Returns & leverage

See full
Return on equity-343.8%-1,012pp
Debt / equity-0.5×
Current ratio7.6×-0.7×

Where this comes from

Reported directly by AnaptysBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: AnaptysBio, Inc.’s 10-Q, filed May 12, 2026.

Filed
May 12, 2026, 4:20 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-219515

Pursuant to the terms of the Vanda License Agreement, we received an upfront payment of $10.0 million for the license and a $5.0 million payment for existing drug supply. We allocated the total transaction price of $15.0 million on a relative standalone selling price in accordance with ASC 606. During the three months ended March 31, 2026, we recognized no license revenue and less than $0.1 million of transition services revenue. During the three months ended March 31, 2025, we recognized $9.6 million of license revenue and $0.1 million of transition services revenue, under ASC 606, and recognized $1.9 million related to existing drug supply transferred to Vanda, under ASC 610. We expensed the $2.5 million of related transaction costs within general and administrative

Item 1. Consolidated Financial Statements

FAQ

What is AnaptysBio, Inc.'s license — revenue?
AnaptysBio, Inc. (ANAB) reported license — revenue of $0 in Q1 2026.
How has AnaptysBio, Inc.'s license — revenue changed year-over-year?
AnaptysBio, Inc.'s license — revenue decreased by 100.0% year-over-year, from $9.6M to $0.
What does license — revenue mean?
This metric captures the total revenue recognized from licensing intellectual property or technology rights to third-party customers, excluding any pass-through taxes. It serves as a primary indicator of the commercial value of the company's proprietary antibody pipeline and research platform. Monitoring this figure helps stakeholders evaluate the success of the company's business model in converting clinical-stage assets into contractual revenue streams.

Ask your AI about AnaptysBio, Inc.'s license — revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude